Ziphius develops a self-amplifying RNA (saRNA) platform for the rapid and scalable manufacturing of innovative medical tools addressing public health needs. This platform utilizes proprietary Lipid Nanoparticles (LNP) optimized for saRNA delivery, stability, and various administration routes. The technology aims to deliver higher protein expression at lower dosages for applications spanning infectious disease vaccines, rare disease therapies, and oncology treatments.
Funding
$51.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional mRNA vaccines require high dosages due to limited protein production from a single transcript, potentially leading to increased side effects and manufacturing costs. Existing delivery methods may also lack the efficiency to target specific organs or tissues, limiting therapeutic efficacy.
Solution
Ziphius Vaccines is developing self-amplifying RNA (saRNA) vaccines that utilize a proprietary lipid nanoparticle (LNP) platform for targeted delivery and enhanced stability. The saRNA technology amplifies the copy number of coding sequences from a single transcript, enabling higher protein production at lower dosages compared to conventional mRNA vaccines. The in-house developed LNP library is designed to ensure proper encapsulation and biodegradability of the LNP-saRNA complex, with ongoing optimization to target specific organs and tissues, minimize toxicity, and maximize prophylactic or gene supplementation effects. This approach aims to create more effective and scalable vaccine solutions for infectious diseases and gene supplementation therapies for rare genetic disorders.
Target Audience
The primary target audience includes individuals at risk of infectious diseases and patients with rare genetic disorders who could benefit from gene supplementation therapies.
Features
- Proprietary lipid nanoparticle (LNP) library specifically designed for saRNA delivery
- saRNA technology for amplified protein production from a single transcript
- Targeted delivery to specific organs and tissues to maximize therapeutic effect
- Enhanced stability and biodegradability of the LNP-saRNA complex
- Lower dosage requirements compared to conventional mRNA vaccines